Table 4

Pulmonary function tests and 6MWD at baseline and end of treatment

Omeprazole (n=20)Placebo (n=20)Adjusted between group difference (omeprazole minus placebo) at end of treatment (95% CI)
BaselineEnd of treatmentBaselineEnd of treatment
FEV1 n=19*n=20
Measured (L)2.10 (0.53)2.05 (0.63)1.99 (0.57)2.07 (0.52)−0.12 (−0.25 to −0.002)†
% predicted78.6 (15.7)75.8 (18.0)77.9 (19.2)82.6 (19.4)−7.4 (−14.6 to −0.2)†
FVCn=19*n=20
Measured (L)2.57 (0.71)2.48 (0.77)2.50 (0.65)2.53 (0.66)−0.11 (−0.21 to − 0.02)
% predicted75.0 (17.9)71.1 (18.7)77.9 (17.6)78.1 (18.3)−5.1 (−9.4 to −0.8)
FEV1/FVCn=19*n=20
%0.82 (0.04)0.83 (0.07)0.80 (0.13)0.83 (0.07)0.00 (−0.04 to 0.04)
Kcon=18*, ‡n=18§
Measured (mmol/min/kPa/L)1.18 (0.29)1.21 (0.31)1.11 (0.27)1.04 (0.28)0.11 (0.002 to 0.22)
% predicted90.7 (21.7)94.3 (23.1)85.3 (22.6)80.3 (22.7)9.3 (0.9 to 17.6)
TLcon=18*, ‡n=18§
Measured (mmol/min/kPa)4.42 (1.60)4.39 (1.53)3.98 (1.28)3.80 (1.43)0.19 (−0.30 to 0.68)
% predicted52.4 (15.8)52.1 (14.4)50.1 (15.8)47.7 (16.2)2.5 (−3.1 to 8.0)
6MWDn=19*n=19¶
Measured (metres)408.5 (102.6)386.3 (130.6)372.4 (112.7)381.1 (109.9)−30.4 (-68.9 to 8.1)**
  • Data are presented as mean (SD).

  • *Assessments not performed as participant in hospital with sepsis.

  • †Model has poor fit due to outlying values for one participant.

  • ‡Participant unable to breath-hold, hence gas transfer not measurable.

  • § One participant unable to perform full PFTs and one participant had poor technique in lung function at baseline. Unable to measure gas transfer factors.

  • ¶Walk test not performed due to above knee amputation.

  • ** Model has poor fit due to an outlying value for one participant.

  • 6MWD, 6 min walk distance; TLco, transfer factor for carbon monoxide.